DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.
据报道，佛罗里达州州长罗恩·德桑蒂斯政府已发布最新指南，建议医疗保健提供者引导弱势患者远离基于 mRNA 的 COVID-19 疫苗。
The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.
佛罗里达州卫生部对mRNA疫苗的安全性表示担忧，指出潜在风险，例如心肌炎和体位性心动过速综合征（POTS），罕见的心脏病。这种立场与联邦卫生机构的建议形成鲜明对比，后者继续认可mRNA疫苗对所有符合条件的个人都是安全有效的。
In June, the U.S. CDC recommended using updated 2024-2025 COVID-19 vaccines in individuals six months and older.
6月，美国疾病预防控制中心建议六个月及以上的人使用更新后的 2024-2025 年 COVID-19 疫苗。
The FDA in August granted emergency use approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX), targeting the Omicron variant KP.2 strain.
美国食品药品管理局在8月批准了莫德纳公司（纳斯达克股票代码：MRNA）和辉瑞公司（纽约证券交易所代码：PFE）/BioNTech SE（纳斯达克股票代码：BNTX）针对奥密克戎变体KP.2菌株的更新型基于mRNA的 COVID-19 疫苗的紧急使用许可。
Also Read: Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows.
另请阅读：长期的Covid仍然是诊断之谜，诊断仍然难以捉摸；国立卫生研究院资助的研究表明。
The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.
美国全国广播公司新闻强调，该州卫生部门建议65岁及以上的人以及有潜在健康状况的人优先获得非mRNA疫苗和治疗。
Earlier this month, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:NVAX) protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.
本月早些时候，美国食品药品管理局向Novavax Inc.授予了紧急使用授权。”s（纳斯达克股票代码：NVAX）基于蛋白质的 COVID-19 疫苗，辅助剂（2024-2025 年配方）（NVX-CoV2705）用于主动免疫，预防 12 岁及以上人群的 COVID-19。
The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.
该州的指导方针强调，先前感染的高免疫水平加上当前的数据，证明了他们的立场是合理的。
The report adds that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.
该报告补充说，尽管记录在案的与mRNA疫苗相关的心肌炎风险很小，尤其是在年轻男性中，但研究表明，大多数病例是轻度的，可以完全缓解。
Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.
发表在《自然心血管研究》上的研究强调，COVID-19 感染者患上POTS的可能性是接种mRNA疫苗的人的五倍，这凸显了疫苗接种的重要性。
Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes.
剑桥大学、布里斯托尔大学和爱丁堡大学的研究人员透露，接种 COVID-19 疫苗可以显著降低动脉血栓的发病率，动脉血栓是心脏病发作和中风的主要原因。
Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.
价格走势：在周一的最后一次支票中，MRNA股价上涨2.37％，至69.90美元，PFE股价上涨2.12％，至29.89美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：此内容部分是在人工智能工具的帮助下制作的，并由Benzinga的编辑审阅和发布。
- BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report.
- 必和必拓集团对铜供应发出警报，人工智能和电动汽车的增长可能推动价格飙升：报告。
Image via Shutterstock
图片来自 Shutterstock